• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Endocrinology

Weight loss interventions may improve metabolic and reproductive outcomes in polycystic ovarian syndrome

byAdrian Wong, BHScandThomas Su
November 4, 2024
in Endocrinology
Reading Time: 3 mins read
Letrozole (Femara) boosts fertility of women with Polycystic Ovarian Syndrome
Share on FacebookShare on TwitterShare on LinkedIn

1. In this systematic review and meta-analysis, weight loss interventions for overweight people with polycystic ovary syndrome were associated with greater reductions in insulin resistance and free androgen index as well as greater increases in menstruation frequency.

2. Weight loss interventions were also linked to greater reductions in fasting insulin with no effect on fasting glucose.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Over half of women with polycystic ovary syndrome (PCOS) are overweight or obese, which has been linked to worse metabolic, hormonal, and reproductive outcomes. Clinical guidelines recommend that these women be encouraged to lose weight, but women often find that advice alone can be unhelpful; furthermore, the effects of weight loss on the full range of symptoms and markers has yet to be well described. This study aimed to assess how weight loss intervention programs affect metabolic, hormonal, and gynecological markers as well as quality of life among women with PCOS. Primary analyses showed that, compared to usual care alone, weight loss intervention resulted in a nearly 4 kilogram reduction in weight and larger reductions in insulin resistance and free androgen index (FAI). Frequency of menstruation was also found to increase to a greater degree among those who received weight loss intervention. Weight loss interventions were linked to larger reductions in fasting insulin, testosterone, and sex hormone-binding globulin (SHBG), but there were no clinically significant changes in fasting glucose, follicular stimulating hormone (FSH), luteinizing hormone (LH), hirsutism, and PCOS quality of life. Notably, adverse events were more common among participants receiving weight loss intervention, primarily due to gastrointestinal effects of pharmacotherapy. The generalizability of this study was limited by high statistical heterogeneity; lack of precision and inconsistent confidence intervals in several analyses; and a high risk of bias in some of the studies used. Nevertheless, this study demonstrated how weight loss interventions may attenuate the effects of PCOS among women who are overweight.

Click to read this study in the Annals of Internal Medicine

Relevant Reading: Exercise, or exercise and diet for the management of polycystic ovary syndrome: a systematic review and meta-analysis

RELATED REPORTS

Medicaid-reimbursed weight-loss GLP-1 prescriptions fell after coverage withdrawal in 4 states

Investigational retatrutide reduced knee osteoarthritis pain and body weight versus placebo in adults with obesity

In-Depth [systematic review and meta-analysis]: This study examined 39 randomized controlled trials to assess the impact of weight loss intervention programs on various metabolic, hormonal, and gynecological outcomes among people with PCOS and overweight or obesity. Weight loss interventions included dietary modification, physical activity, pharmacotherapy, bariatric surgery, or combinations of these treatments; control measures entailed standard of care, including metformin, oral contraceptives, and standard advice. Primary outcomes were biomarkers and symptoms of PCOS, including Homeostasis Model Assessment for Insulin Resistance (HOMA-IR), fasting insulin, fasting glucose, total testosterone, FAI, SHBG, LH, FSH, menstruation frequency, hirsutism, and quality of life measures. Primary analyses compared more intense weight loss interventions with less intense weight loss interventions, while secondary analyses compared weight loss interventions with any intervention that was of lower intensity. Weight loss interventions resulted in a weight change of -3.78 kg (95% CI, -4.61 to -2.94) in the primary analysis and -3.43 kg in the secondary analysis (95% CI, -4.08 to -2.77). The mean difference (MD) in change in HOMA-IR associated with weight loss interventions was -0.45 (95% CI, -0.75 to -0.15) in the primary analysis and -0.56 (95% CI, -0.9 to -0.23) in the secondary analysis. The MD in change in FAI associated with weight loss interventions was -2.03 (95% CI, -3.0 to -1.07) in the primary analysis and -1.37 (95% CI, -2.43 to -0.31) in the secondary analysis. The MD in change in menstruation frequency associated with weight loss interventions was 2.64 (95% CI, 0.65 to 4.63) menses per year in the primary analysis and 1.88 (95% CI, 0.84 to 2.93) menses per year in the secondary analysis. Weight loss interventions were also associated with larger decreases in fasting insulin (-1.28 [95% CI, -2.24 to -0.31]), total testosterone (-0.16 [95% CI, -0.26 to -0.05]), and SHBG (7.46 [95% CI, 2.26 to 12.67]). Overall, despite the heterogeneity of interventions and comparisons, this study clarified the impact of weight loss interventions on PCOS symptoms and biomarkers.

Image: PD

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: blood glucoseinsulin resistancemenstruationmetabolic disorderPolycystic Ovary Syndromesex hormoneweight loss
Previous Post

Novel colorectal cancer screening tests’ utility depends on patient context

Next Post

Machine learning algorithm shows limited capacity for reducing health spending for radiation therapy outpatients

RelatedReports

GLP-1 medicines and aging collage: a smiling white-haired man with a mustache beside a bonsai tree and a capped injection pen
All Specialties

Medicaid-reimbursed weight-loss GLP-1 prescriptions fell after coverage withdrawal in 4 states

November 18, 2026
Knee osteoarthritis collage: a calm older man with a gray beard, a knee joint inset with teal cartilage and a knee brace
Endocrinology

Investigational retatrutide reduced knee osteoarthritis pain and body weight versus placebo in adults with obesity

November 17, 2026
Obesity collage: walking shoes, a plate of vegetables and grains, a coiled cloth measuring tape and a glass of water
All Specialties

In a randomized sham-controlled trial, acupoint thread embedding produced a between-group difference in change from baseline of 1.8 kg at 12 weeks and 3.0 kg at 24 weeks in Chinese women with overweight or obesity

November 16, 2026
A balance scale with a syringe on one side and silhouettes of varying body sizes on the other, symbolizing weight management and GLP-1 medications.
2MM Trial Briefs

In topline phase 3 results, retatrutide lowered A1C more and reduced weight more than semaglutide 2 mg at 80 weeks

October 29, 2026
Next Post

Machine learning algorithm shows limited capacity for reducing health spending for radiation therapy outpatients

#VisualAbstract: Deferoxamine, Deferasirox, and Deferiprone Triple Iron Chelator Combination Therapy for β-Thalassaemia

#VisualAbstract: Deferoxamine, Deferasirox, and Deferiprone Triple Iron Chelator Combination Therapy for β-Thalassaemia

Grading carcinoembryonic antigen levels can enhance prognostic stratification in colorectal cancer

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Inhaled corticosteroids do not improve outcomes in sickle cell disease patients without asthma
  • Interim global phase 2 AZUR-1 results show durable responses with dostarlimab monotherapy in untreated MSI-H/dMMR stage II/III locally advanced rectal cancer
  • AI health chatbot shows no benefit for perinatal anxiety or depression
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.